| 1. |
- Li, Liang, et al.
(författare)
-
A Cosmological Fireball with 16% Gamma-Ray Radiative Efficiency
- 2023
-
Ingår i: Astrophysical Journal Letters. - : American Astronomical Society. - 2041-8205 .- 2041-8213. ; 944:2
-
Tidskriftsartikel (refereegranskat)abstract
- Gamma-ray bursts (GRBs) are the most powerful explosions in the universe. How efficiently the jet converts its energy to radiation is a long-standing problem, which is poorly constrained. The standard model invokes a relativistic fireball with a bright photosphere emission component. A definitive diagnosis of GRB radiation components and the measurement of GRB radiative efficiency require prompt emission and afterglow data, with high resolution and wide band coverage in time and energy. Here, we present a comprehensive temporal and spectral analysis of the TeV-emitting bright GRB 190114C. Its fluence is one of the highest for all the GRBs that have been detected so far, which allows us to perform a high-resolution study of the prompt emission spectral properties and their temporal evolutions, down to a timescale of about 0.1 s. We observe that each of the initial pulses has a thermal component contributing ∼20% of the total energy and that the corresponding temperature and inferred Lorentz factor of the photosphere evolve following broken power-law shapes. From the observation of the nonthermal spectra and the light curve, the onset of the afterglow corresponding to the deceleration of the fireball is considered to start at ∼6 s. By incorporating the thermal and nonthermal observations, as well as the photosphere and synchrotron radiative mechanisms, we can directly derive the fireball energy budget with little dependence on hypothetical parameters, measuring a ∼16% radiative efficiency for this GRB. With the fireball energy budget derived, the afterglow microphysics parameters can also be constrained directly from the data.
|
|
| 2. |
- Reulen, Raoul C, et al.
(författare)
-
Risk Factors for Primary Bone Cancer After Childhood Cancer : A PanCare Childhood and Adolescent Cancer Survivor Care and Follow-Up Studies Nested Case-Control Study
- 2023
-
Ingår i: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. - 0732-183X .- 1527-7755. ; 41:21, s. 3735-3746
-
Tidskriftsartikel (refereegranskat)abstract
- PURPOSE: Radiation to the bone and exposure to alkylating agents increases the risk of bone cancer among survivors of childhood cancer, but there is uncertainty regarding the risks of bone tissue radiation doses below 10 Gy and the dose-response relationship for specific types of chemotherapy.METHODS: Twelve European countries contributed 228 cases and 228 matched controls to a nested case-control study within a cohort of 69,460 5-year survivors of childhood cancer. Odds ratios (ORs) of developing bone cancer for different levels of cumulative radiation exposure and cumulative doses of specific types of chemotherapy were calculated. Excess ORs were calculated to investigate the shape and extent of any dose-response relationship.RESULTS: The OR associated with bone tissue exposed to 1-4 Gy was 4.8-fold (95% CI, 1.2 to 19.6) and to 5-9 Gy was 9.6-fold (95% CI, 2.4 to 37.4) compared with unexposed bone tissue. The OR increased linearly with increasing dose of radiation ( P trend < .001) up to 78-fold (95% CI, 9.2 to 669.9) for doses of ≥40 Gy. For cumulative alkylating agent doses of 10,000-19,999 and ≥20,000 mg/m 2, the radiation-adjusted ORs were 7.1 (95% CI, 2.2 to 22.8) and 8.3 (95% CI, 2.8 to 24.4), respectively, with independent contributions from each of procarbazine, ifosfamide, and cyclophosphamide. Other cytotoxics were not associated with bone cancer. CONCLUSION: To our knowledge, we demonstrate-for the first time-that the risk of bone cancer is increased 5- to 10-fold after exposure of bone tissue to cumulative radiation doses of 1-9 Gy. Alkylating agents exceeding 10,000 mg/m 2 increase the risk 7- to 8-fold, particularly following procarbazine, ifosfamide, and cyclophosphamide. These substantially elevated risks should be used to develop/update clinical follow-up guidelines and survivorship care plans.
|
|
